Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Friday, March 10th. The shares were sold at an average price of $18.05, for a total transaction of $180,500.00. Following the sale, the insider now owns 1,233,660 shares of the company’s stock, valued at approximately $22,267,563. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $18.92 on Wednesday. Day One Biopharmaceuticals, Inc. has a 1-year low of $5.44 and a 1-year high of $28.35. The business’s fifty day moving average price is $20.57 and its two-hundred day moving average price is $20.78. The company has a market capitalization of $1.39 billion, a P/E ratio of -8.72 and a beta of -1.94.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DAWN. Quantbot Technologies LP bought a new position in Day One Biopharmaceuticals in the 2nd quarter valued at about $51,000. UBS Group AG acquired a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter worth approximately $69,000. Amalgamated Bank boosted its holdings in shares of Day One Biopharmaceuticals by 21.0% in the third quarter. Amalgamated Bank now owns 3,577 shares of the company’s stock valued at $72,000 after acquiring an additional 620 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Day One Biopharmaceuticals by 58.6% during the first quarter. California State Teachers Retirement System now owns 9,687 shares of the company’s stock valued at $96,000 after acquiring an additional 3,581 shares during the period. Finally, American International Group Inc. raised its holdings in Day One Biopharmaceuticals by 92.7% during the first quarter. American International Group Inc. now owns 11,294 shares of the company’s stock worth $112,000 after purchasing an additional 5,434 shares in the last quarter. 86.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of recent research reports. The Goldman Sachs Group boosted their price objective on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a “buy” rating in a research report on Monday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $48.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 7th. Bank of America began coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a “buy” rating and a $34.00 price objective for the company. Oppenheimer assumed coverage on Day One Biopharmaceuticals in a research note on Thursday, February 2nd. They set a “market perform” rating for the company. Finally, Piper Sandler raised their target price on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Sunday, January 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $44.14.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.